Trial Profile
Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a TB Endemic Region.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 01 Nov 2018 Results (n=214) published in the Medicine
- 11 Jul 2013 Planned End Date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Planned end date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.